Online Video of InVitria’s Zap-CHO Helps Scientists Maximize CHO Cell Culture PerformanceLooking for the ultimate CHO cell culture supplement? InVitria has what scientists have been asking for! Zap-CHO is a robust CHO cell culture media supplement that improves the growth and productivity of CHO cells. Developed for scientists seeking maximum CHO cell culture performance, Zap-CHO is an animal free, well defined and consistent recombinant CHO supplement. Fort Collins, CO December 15, 2009 – Scientists working with CHO cells can now access an informational online video featuring a presentation by Dr. Steve Pettit, InVitria’s Director of Cell Culture Product Development. Zap-CHO is a robust CHO cell supplement that maximizes CHO cell line performance and speeds-up cell line development processes. Zap-CHO is not a hydrolysate; it is an animal free, well defined and consistent recombinant CHO supplement.
Dr. Pettit guides viewers through the online video by describing the work done to test the effectiveness of Zap-CHO on CHO cell growth and productivity. “We tested Zap-CHO in the leading chemically-defined, serum- and protein-free cell culture media available on the market today,” said Dr. Pettit. “In our tests, Zap-CHO increased cell growth an average of 190% across all media and extended cell viability by delaying apoptosis. Most importantly, Zap-CHO increased volumetric productivity an average of 179%.”
In the video, Dr. Pettit points out the distinct advantages Zap-CHO gives scientists who are trying to improve their CHO cell line performance, including:
Further, Zap-CHO helps scientists working in clone selection by improving growth and shortening timelines; in seed train expansion by reducing the amount of time from cell bank to bioreactor; in cell adaptation by reducing the timelines for media adaptation; and, in bioproduction by maximizing antibody titre.
To watch the Zap-CHO product video, click here.
To purchase Zap-CHO: About http://www.InVitria.com
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
